Aclid, a NYC-based provider of a security and compliance automation platform for the biotechnology industry, raised $3.3M in Seed funding.
The round was led by 2048 Ventures and IA Ventures.
The company intends to use the funds to meet customer demand for its real-time screening and verification platform.
Led by Founder and CEO Kevin Flyangolts and Harris Wang, Aclid provides a security and compliance automation platform for biotechnology. Gene synthesis providers use it to verify customers, screen DNA and RNA orders for pathogenic and toxic elements, and automate compliance checks.
FinSMEs
12/10/2023